

24 October 2019

Lægemiddelstyrelsen  
Kliniske forsøg  
Axel Heides Gade 1  
2300 København S  
Danmark

## **Termination of the clinical trial ENGOT-Cx7-NSGO/MaRuC with EudraCT 2018-003756-20**

Dear Lægemiddelstyrelsen,

We, Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), regret to inform that the ENGOT-Cx7-NSGO/MaRuC has been terminated earlier than planned.

Unfortunately, the grant provider pharmaceutical company Clovis has decided to terminate the support due to their critical financial status. Fortunately, no patients are screened/informed/enrolled in the study.

**Approved protocol:** Version 1.2, dated 14 June 2019

A notification for early termination is submitted to the ethics committee (De Videnskabetiske Komiteer for Region Hovedstaden) in parallel.

If you have any questions or concerns about this termination, please do not hesitate to contact us at +45 35 45 33 11 or by email [kirsten.pors@regionh.dk](mailto:kirsten.pors@regionh.dk)

Yours sincerely,

**Mansoor Raza Mirza, MD**

Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU)  
Department of Oncology, 9431  
Rigshospitalet, Copenhagen University Hospital  
Blegdamsvej 9, 2100 Copenhagen Ø, Denmark  
[mansoor.raza.mirza@gmail.com](mailto:mansoor.raza.mirza@gmail.com)